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Abstract We assessed the effects of 12 months of non-
pharmacological and pharmacological therapy on 24-h
ambulatory blood pressure, regression of target organ
damage (TOD) and metabolic abnormalities in 86 children
(14.1±2.4 years) with primary hypertension. Twenty-four
hour systolic and diastolic blood pressure (BP) decreased
(130±8 vs 126±8, 73±7 vs 70±7, p=0.0001 and 0.004
respectively). Body mass index (BMI) did not change, but
waist-to-hip (0.85±0.07 vs 0.83±0.05, p=0.01) and waist-
to-height ratio (WHtR; 0.49±0.07 vs 0.48±0.05, p=0.008)
decreased. Left ventricular mass index (LVMi; 38.5±10.7 vs
35.2±7.5 g/m
2.7, p=0.0001), prevalence of left ventricular
hypertrophy (46.5% vs 31.4%; p=0.0001), carotid intima-
media thickness (cIMT; 0.44±0.05 vs 0.42±0.04 mm, p=
0.0001), wall cross sectional area (WCSA; 7.5±1.3 vs 6.9±
1.2 mm
2, p=0.002), hsCRP (1.1±1.0 vs 0.7±0.7 mg/l, p=
0.002), and LDL-cholesterol (115±33 vs 107±26 mg/dl, p=
0.001) decreased. Patients who had lowered BP had a lower
cIMT at the second examination (0.41±0.04 vs 0.43±
0.04 mm, p=0.04) and lower initial hsCRP values (0.9±0.7
vs 1.5±1.3 mg/l, p=0.04) in comparison to non-responders.
Regression analysis revealed that the main predictor of
LVMi decrease was a decrease in abdominal fat expressed as
a decrease in waist circumference (WC) (R
2=0.280, β=
0.558, p=0.005), for WCSA-SDS a decrease in WC (R
2=
0.332, β=0.611,p=0.009) and for a cIMT-SDS decrease the
main predictor was a decrease in hsCRP concentrations (R
2=
0.137, β=0.412, p=0.03). Standard antihypertensive treat-
m e n tl o w e r e dB Pa n dl e dt or e g r e s s i o no fT O Di n
hypertensive children. Lean body mass increase and decrease
in abdominal obesity correlated with TOD regression.
Keywords Primary hypertension.Target organ damage.
Arteriosclerosis.Metabolic syndrome.Left ventricular
hypertrophy.Children
Introduction
Primary hypertension (PH) in childhood and adolescence is
not a benign disease and causes significant target organ
M. Litwin
Department of Research,
The Children’s Memorial Health Institute,
Al. Dzieci Polskich 20,
Warsaw 04-730, Poland
M. Litwin (*): A. Niemirska:J. Śladowska-Kozlowska
Department of Nephrology & Arterial Hypertension,
The Children’s Memorial Health Institute,
Al. Dzieci Polskich 20,
Warsaw 04-730, Poland
e-mail: m.litwin@czd.pl
A. Wierzbicka: Z. T. Wawer
Department of Biochemistry & Experimental Medicine,
The Children’s Memorial Health Institute,
Al. Dzieci Polskich 20,
Warsaw 04-730, Poland
R. Janas
Department of Radioimmunology,
The Children’s Memorial Health Institute,
Al. Dzieci Polskich 20,
Warsaw 04-730, Poland
A. Wisniewski
Department of Physiology,
Jozef Pilsudski University of Physical Education,
Warsaw, Poland
J. Feber
Department of Pediatrics, Division of Nephrology,
Children’s Hospital of Eastern Ontario, University of Ottawa,
Ottawa, Canada
Pediatr Nephrol (2010) 25:2489–2499
DOI 10.1007/s00467-010-1626-7damage (TOD), which is already present at diagnosis [1, 2].
Although clinically evident cardiovascular disease is rare in
childhood, it is known that the extent of TOD is the main
risk factor for future cardiovascular events [3]. Thus, the
efficacy of antihypertensive treatment should be evaluated
not only in terms of blood pressure (BP) lowering, but also
in terms of regression of TOD and metabolic abnormali-
ties. As cardiovascular events are extremely rare in
childhood, it is the TOD regression or progression that
can be used as an intermediate end-point in prospective
studies in pediatric patients. To date, there have been only
limited data on the effectiveness of antihypertensive
treatment in children with PH and even fewer data exist
on the regression of TOD [4–6].
The evaluation of the effects of antihypertensive therapy,
bothpharmacologicalandnon-pharmacological,onmetabolic
abnormalities accompanying PH in children and adolescents
is challenging. Usually, both the non-pharmacological and
pharmacological therapies are used together and therefore it is
difficult to separate the effects of these two interventions.
Obesity or being overweight is the main intermediate
phenotype of children with PH; metabolic abnormalities are
linked pathophysiologically to increased abdominal obesity
and are the main determinants of TOD in hypertensive
children. This is why non-pharmacological treatment based
on life-style modifications is supposed to be effective for both
BP lowering and normalization of metabolic abnormalities.
Thus, to determine the main predictors of TOD regression we
performed a prospective, observational study in children with
PH who underwent 12 months of standard pharmacological
and non-pharmacological therapy.
Patients and methods
The study adhered to the principles of the Declaration of
Helsinki and was approved by the local Ethics Committee.
Informed consent was obtained from all control subjects
and hypertensive patients and their parents.
Patients
All children with newly diagnosed PH at our institution in
the period from 2005 to 2008 were considered as study
candidates. We included 86 adolescents (66 boys, 20 girls)
aged 14.1±2.4 years (range: 5–17). Exclusion criteria were:
presence of any significant chronic disease (except for PH)
including diabetes and chronic kidney disease, any acute
disease including infections in the 6 weeks preceding
enrollment, and incomplete data. All measurements were
performed at diagnosis of PH and then after 12 months of
standard antihypertensive therapy, including pharmacolog-
ical and non-pharmacological treatment.
Primary hypertension was diagnosed after a thorough
clinical and laboratory diagnostic work-up, and exclusion
of known secondary causes of hypertension. In all patients
serum creatinine, urea, ions, blood gases, lipids, glucose,
renal Doppler ultrasound, renal scintigraphy, and urinary
catecholamines were evaluated. Normal office BP values
were taken from the Updated 4th Task Force Report [7].
In all patients the diagnosis was confirmed by 24-h
ambulatory blood pressure monitoring (ABPM). ABPM
was performed at the initial visit and at the last follow-up
after 12 months. Recordings lasting at least 20 h with at
least 80% of valid measurements were included to the
analysis. BP values were calculated from the ABPM as the
mean 24-h systolic (SBP) and diastolic (DBP) blood
pressure and presented as absolute values and as the
systolic and diastolic blood pressure index (SBPi and DBPi
respectively), calculated as the ratio of SBP or DBP to the
95th percentile for height and gender based on the pediatric
ABPM reference data [8, 9]. Patients were considered to be
hypertensive if their SBPi and/or DBPi were equal to or
exceeded 1.0 (i.e. BP was above the 95th percentile) at the
start of the therapy. We used a recently published
classification system based on ABPM to classify patients
as having normal blood pressure, ambulatory hypertension,
and severe ambulatory hypertension [9]. Ambulatory
hypertension was defined as mean ambulatory SBP above
the 95th percentile and SBP load between 25 and 50%, and
severe ambulatory hypertension was defined as mean
ambulatory SBP above the 95th percentile and SBP load
above 50%. Normotension was defined as mean ambulato-
ry SBP below the 95th percentile and SBP load below 25%.
Pre-hypertension was defined as the mean SBP below the
95th percentile and SBP load was in the range 25–50%.
All patients underwent the following assessments:
anthropometrical measurements including body mass index
(BMI), waist-to-hip ratio (WHR), and waist-to-height ratio
(WHtR), bloodpressure,carotidandfemoralsuperficialartery
intima-media thickness (cIMT and fIMT respectively), left
ventricular mass index (LVMi), urinary albumin excretion,
oral glucose tolerance test (OGTT), serum insulin, blood
lipids, serum homocysteine, serum uric acid, and C-reactive
protein (hsCRP). Obesity and being overweight were diag-
nosed according to the International Obesity Task Force
(IOTF) recommendations [10]
Intima-media thickness measurements
Carotid and femoral superficial artery intima-media thickness
(cIMT and fIMT) were evaluated by ultrasound according to
the methodology described previously [11]. The median and
standard deviation (SD) of normal values for cIMTand fIMT
were obtained from a study of 250 healthy children
published elsewhere [11].
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formulas described previously [12]:
& Mean systolic diameter (sD) = (LsD+RsD)/2, where
LsD – left cca systolic diameter; and RsD –right cca
systolic diameter
& Mean diastolic diameter (dD) = (RdD+LdD)/2, where
RdD – right cca diastolic diameter, andLdD – left cca
diastolic diameter
& Meanwallcross sectional area(WCSA)=π(dD/2+IMT)
2-π(dD/2)2
Echocardiography
All echocardiography (ECHO) examinations were per-
formed by one examiner who knew the clinical diagnosis,
but was not aware of the severity of PH and the
effectiveness of treatment. ECHO measurements were
performed according to American Society of Echocardiog-
raphy guidelines. To standardize the left ventricular mass to
height, the left ventricular mass index (LVMi) was
calculated according to the deSimone formula [13, 14].
Left ventricular hypertrophy (LVH) was defined as LVMi
value above 38.6 g/m
2.7 (95th percentile), and a LVMi
equal to or greater than 51 g/m
2.7 was the cut-off for severe
LVH [7, 12–14]. In addition, because it was recently
proposed that the 95th percentile of LVMi indexed to
height should also be age- and gender-specific we used
reference data published by Khoury et al. [15].
Laboratory investigations
Blood samples were taken after 12 h of fasting and were
immediately sent to the laboratory. OGTT was done after
oral ingestion of 1 g/kg (maximum 75 g) of glucose. The
blood samples were taken via venous catheter at 30-min
intervals. The plasma glucose level was measured by a
Dimension analyzer. Plasma insulin concentration was
measured by radioimmunoassay (RIA). Serum adiponectin
and leptin levels were measured by an ELISA using a
commercially available kit (LINCO Research).
Insulin resistance was expressed as homeostasis model
assessment for insulin resistance (HOMA-IR) and as the
Insulin Sensitivity Index (ISI [0,120]) according to the
formula developed by Gutt et al. [16]. ISI [0,120] highly
correlated with insulin sensitivity measured by the eugly-
cemic hyperinsulinemic clamp method. ISI was defined as
(m/MPG/logMSI) where:
& m = [ingested glucose in mg + (fasting glucose in mg/dl –
2-h glucose in mg/dl) ×0.19 × body weight (kg)]/120 min
& MPG = mean of fasting and 2-h glucose concentrations
(in mg/dl)
& MSI = mean of fasting and 2-h insulin concentrations
(mU/ml)
& ISI [0,120] was expressed as mg × L2/mmol × mU × min
& A low value of ISI [0,120] indicates greater insulin
resistance
Plasma homocysteine was measured with fluorescence
polarization immunoassay (IMX®; Abbott) for the quanti-
tative measurement of total L-homocysteine. The hsCRP
concentration was determined using highly-sensitive immu-
noturbidimetry (Orion Diagnostica). Serum creatinine was
measured with a modified Jaffe reaction. Glomerular
filtration rate was estimated using the Schwartz formula
with a K value of 0.55 for girls aged 13–17 and children
below 13 years of age, and a K value of 0.7 for boys aged
13–17 years of age [17].
Definition of metabolic syndrome
Because there are no national reference data for waist
circumference in children, metabolic syndrome (MS) was
diagnosed according to criteria described previously [18].
Antihypertensive treatment
At enrollment no one patient was treated pharmacologically
or received any advice about non-pharmacological treat-
ment. After diagnosis of PH all patients were informed
about the principles of non-pharmacological treatment
including life-style changes, increase in physical activity,
and dietary modifications including salt avoidance, and
were referred to an external consultant (AW). We encour-
aged patients to increase general physical activity up to
90 min daily including sport activity, walking, climbing
stairs, etc. The nature of the activity (playing football,
jogging, aerobic, walking, biking, etc.) was chosen by
patients according to personal preferences. Dietary mod-
ifications were based on a significant reduction of salt use
both by patients and family members, and a significant
reduction in sugar.
Pharmacological treatment was immediately started in
patients who had a significant TOD (LVMi>51 g/height
2.7
and/or cIMT or WCSA>2 SDS) and/or severe ambulatory
hypertension. BP was checked at 3 and 6 months during
ambulatory visits. If after 3 or 6 months office BP was still
within the hypertensive range, ABPM was performed. In
patients who still had ambulatory or severe ambulatory
hypertension, pharmacotherapy was started or another drug
was given. Finally, ABPM was performed again after
12 months of treatment.
Patients who after 12 months of treatment had lower
ABP below the 95th percentile were treated as responders
and those who did not have lower BP below the 95th
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the angiotensin-converting enzyme inhibitor (ACEi) ena-
lapril (0.2–0.3 mg/kg/day bid). Patients who had asthma or
did not tolerate ACEi were prescribed the angiotensin 2
receptor type 1 blocker (ARB) losartan at a dosage of 0.7–
1 mg/kg/day in one or two daily doses. If patients were
unable to buy the prescribed medications (enalapril or
losartan), amlodipine was used with a standard dosage of
5 mg once daily.
Allpatients,boththosetreatedonlynon-pharmacologically
and those treated non-pharmacologically and with antihyper-
tensive drugs were evaluated in regular 3-month intervals
duringroutineambulatory,out-patientvisits.Theadherenceto
lifestylemodificationswasassessedbyinterviewwithpatients
andparents.Whentheantihypertensiveeffectwasinadequate,
amlodipine as the second drug was prescribed and in patients
treated only with lifestyle intervention, therapy with ACEi,
ARB or amlodipine was started. Patients who were still
hypertensive after 6 monthsand fulfilled the criteriaof stage 2
hypertension based on home and casual BP measurements
were prescribed metoprolol at a dosage of 0.5 mg/day as the
third drug.
Statistical analysis
Because the groups analyzed included subjects of different
ages and genders, BMI and IMT values were expressed
both as absolute values and as SDS for age and gender.
LVM values in grams were standardized to height in
meters
2.7 and were also expressed as SDS for age and
gender. The change in the measured parameters was
expressed as a delta value (Δ), i.e. the difference between
measurement at 12 months and at the start of treatment.
Homogeneity of variance was checked with Levene’s
test. Continuous variables with a normal distribution were
compared using Student’s t test for independent variables.
Continuous values with non-normal distribution were
compared using the Mann–Whitney U test. Measured
parameters at the start and after 12 months of treatment
were compared using the Wilcoxon test. Dichotomous
variables were compared using the Chi-squared test.
Correlation analysis was performed using Spearman’s
test. LVMi, absolute and standardized IMT, and Δ for blood
pressure, and LVMi and markers of arterial wall thickness
were dependent variables. Because in correlation analysis
and step-wise regression analysis the dependent variables
were standardized values of LVM and IMT, both genders
were analyzed together. Variables with significant correla-
tion were then included in the step-wise multiple regression
analysis.
A p value less than 0.05 was regarded as statistically
significant. A p value ranging between 0.05 and 0.1 was
regarded as a statistical tendency.
Results
Clinical and demographic characteristics
At the start of treatment, 36 out of 86 (41.9%) patients had
severe ambulatory hypertension and 50 (58.1%) had
ambulatory hypertension. On average, patients were obese
and their mean (±SD) BMI-SDS was 1.8±1.8. Being
overweight or obese according to the IOTF criteria was
diagnosed in 56 (65.1%) and 21 (24.4%) patients respec-
tively. Metabolic syndrome was diagnosed in 13 out of 86
(15.1%). According to definitions used in the 4th Task
Report and European Guidelines, LVH was found in 40
(46.5%) and severe LVH was present in 10 patients (11.6%;
Table 1). When we used age- and gender-specific referential
values of 95th percentile of LVMI, LVH was diagnosed in
39 patients (45.3%).
Antihypertensive efficacy of treatment
Throughout the study, 37 patients (43%) who had ambula-
tory hypertensionat thestartand whowere free ofTODwere
prescribed only non-pharmacological therapy, including
dietary advice and an increase in physical activity. Overall,
49 patients were treated pharmacologically of whom 40 with
LVH and/or severe ambulatory hypertension received anti-
hypertensive treatment at the start. Thirty-three patients
(38.3%) received one antihypertensive medication through-
out the study, in 12 patients (14%) the second drug was
added after 3 months of treatment with one drug, and in 4
patients (4.7%) the third drug was added after 6 months of
treatment (Fig. 1).
Overall, after 12 months, the blood pressure lowered
below the 95th percentile in 64 patients (74.4%; respond-
ers; 19 girls, 45 boys). In 10 out of 64 patients in whom
SBP lowered below the 95th percentile the SBP load was
still within the range 25–50% and they fulfilled criteria to
diagnose pre-hypertension. Twenty-one patients (24.4%; 1
girl, 20 boys) still had ambulatory hypertension and 1
(1.2%) had severe ambulatory hypertension, and the
decrease in the severity of hypertension was significant
(χ
2=8.151; p=0.004). Patients who had normalized BP did
not differ in terms of age in comparison to those patients
whodidnothavenormalizedBP(14.0±3.0vs14.7±1.5,n.s.).
BP normalized significantly more often in girls than in boys
(χ
2=9.856; p=0.002).
Of the 37 patients in whom only non-pharmacological
treatment was prescribed 26 patients had lowered BP
and 11 were still hypertensive (ambulatory hypertension).
Of 49 patients treated pharmacologically and non-
pharmacologically, 38 patients had lowered BP, in
10 patients BP was still hypertensive (ambulatory hyper-
tension), and 1 patient still had severe ambulatory hyper-
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were prescribed pharmacotherapy compared with patients
treated only with life-style modifications (−6±10 vs −1±
8 mmHg, p=0.01 for SBP and −5±10 vs 0.5±5 mmHg, p=
0.01 for DBP).
In the whole group, BMI, BMI-SDS, prevalence of
being overweight (50 patients, 58.1%) or obese (24 patients,
27.9%) did not change, but WHR and WHtR decreased
significantly. The prevalence of metabolic syndrome de-
creased after 12 months by 50% (13 vs 6 patients; Chi
2=
13.358, p=0.0001). In addition, the total cholesterol, LDL
cholesterol, hsCRP, lipoprotein (a), and leptin concentra-
tions decreased significantly and there was tendency toward
lower uric acid (Table 2).
At the start of treatment responders had lower concen-
trations of homocysteine (9.5±2.5 vs 10.6±2.0 μmol/l; p=
0.04) and hsCRP (0.9±0.7 vs 1.5±1.3 mg/l; p=0.04) and
tended to have lower concentrations of uric acid (5.3±1.2
vs 5.8±1.3 mg/dl; p=0.06). Responders also had lower
values of fIMT-SDS at the start (0.5±2.3 vs 1.0±1.9; p=
0.05) and lower cIMT after 12 months of treatment (0.41±
0.03 vs 0.43±0.04 mm, p=0.04). Insulin resistance
(ΔHOMA-IR) decreased in responders and increased in
non-responders (−0.2±1.5 vs 0.6±1.9; p=0.03).
Regression of TOD
After 12 months of treatment the average values of LVMi,
cIMT, cIMT-SDS, WCSA, and WCSA-SDS decreased
significantly (Table 2). LVMi decreased significantly in
58 patients (14 girls, 44 boys, n.s.). The proportion of
patients with LVH decreased from 46.5% (40 patients) at
the start of treatment to 31.4% (27 patients) after 12 months
(χ
2=23.660, p=0.0001) as well as the proportion of
patients with severe LVH (from 10 cases to 1 case; χ
2
7.606, p=0.006). When we used age- and gender-specific
reference values of the 95th percentile of LVMi, the
proportions of patients with LVH decreased from 39 patients
to 24 (27.9%; χ
2=15.362, p=0.0001).
Neither the responder nor the non-responder group
differed regarding prevalence of LVH and severe LVH at
the start and after 12 months.
Comparison of patients divided into groups according to
the regression of TOD or the stabilization/progression of
TOD revealed that there were no differences between groups
in terms of change in blood pressure, age, BMI, metabolic
variables and type of therapy (non-pharmacological only vs
non-pharmacological and pharmacological). However, the
only variables that differed between groups was the decrease
in abdominal fat expressed as a decrease in WHR and the
waist circumference (WC), the increase in insulin sensitivity,
and the larger decrease in hsCRP in patients with regression
of TOD (Table 3). Moreover, the decrease in cIMT, LVMi,
and WCSA did not correlate with the change in BP, but
there was significant correlation between the decrease in
WCSA, WCSA-SDS, and LVMi with the decrease in
abdominal fat expressed as the decrease in WHR, WHtR,
and WC (Figs. 2, 3; Table 4).
To find potential predictors of TOD and BP decrease
step-wise regression was used. The variables that differen-
Variable At the start Second evaluation after 12 months
of treatment
p
Girls/boys 20/66
Mean age (years) 14.1±2.4
Height (cm) 169.4±14.8 172.2±13.5 0.0001
Body mass (kg) 72.9±18.8 75.8±17.4 0.0001
BMI (kg/m
2) 25.1±4.7 25.3±4.3 n.s.
BMI-SDS 1.8±1.8 1.8±1.7 n.s.
Waist-to-hip ratio 0.85±0.07 0.83±0.05 0.01
Waist-to-height ratio 0.49±0.07 0.48±0.05 0.008
Normotension 0 54 (62.8%) 0.0001
Pre-hypertension 0 10 (11.6%) 0.0001
Ambulatory hypertension 50 (58.1%) 21 (24.4%) 0.004
Severe ambulatory
hypertension
36 (41.9%) 1 (1.2%) 0.004
24 h SBP (mmHg) 130±8 126±8 0.0001
24 h SBP index 1.03±0.07 0.99±0.06 0.0001
24 h DBP (mmHg) 73±7 70±7 0.004
24 h DBP index 0.95±0.1 0.89±0.1 0.002
24 h SBP load (%) 52.7±28.2 37.5±22.2 0.001
Table 1 Descriptive
demographic, anthropometrical,
and hemodynamic data obtained
at the start and after 12 months
of treatment
BMI body mass index; SBP
systolic blood pressure; DBP
diastolic blood pressure
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and those in whom TOD decreased or not, were chosen
as independent variables. In addition, variables that
correlated with TOD changes (insulin, HOMA-IR, ISI,
hsCRP) were also added, as well as changes in absolute
and indexed BP values. Because a decrease in visceral
obesity was the main correlate of the decrease in TOD,
WC was chosen as a marker of visceral fat decrease. The
step-wise regression analysis revealed that the main
predictor of an LVMi decrease was a decrease in
abdominal fat expressed as a decrease in WC (β=
0.558), explaining about 28% of variability (R
2=0.280,
p=0.005), for WCSA-SDS a decrease in WC (R
2=0.332,
β=0.611, p=0.009), and for the cIMT-SDS decrease the
main predictor was a decrease in hsCRP concentrations
(R
2=0.137, β=0.412, p=0.03).
Discussion
The main finding of our study is that standard non-
pharmacological and pharmacological therapy for adoles-
cents with PH lead to normalization of BP in 74% of cases,
but the main determinant of regression of TOD is the
decrease in abdominal obesity with an increase in lean body
mass and not BP lowering.
Because diagnosis of hypertension is now confirmed by
ABPM we used this method not only for confirmation of
hypertension and exclusion of white coat hypertension, but
also as a tool for assessment of severity of hypertension.
Results of ABPM and especially of SBP load have been
shown to correlate with LVMi in hypertensive children and
better predicted risk of left ventricular hypertrophy than
office blood pressure measurements [19–21]. However,
86 pts with PH 
50 pts with ambulatory HT 
36 pts severe ambulatory HT 
46 pts (with ambulatory HT and no TOD)   40 pts with severe ambulatory HT
and/or TOD 
non-pharmacologic treatment   pharmacologic treatment (one 
         drug)
after 3 mts 
37 pts treated non-pharmacologically     9 pts   49 pts on pharmacological   
                 treatment (37 pts received 1 drug
     with ambulatory    12 pts received 2nd drug) 
       hypertension  
after 6 mts      
 
49 pts on pharmacological  
37 pts treated non -pharmacologically                  treatment (33 pts – one drug 
                  12 pts – two drugs  
                 4 pts – three drugs)  
12 mts 
Assessment of treatment efficacy:  
ABPM, TOD, laboratory evaluation  
Abbreviations: ABPM – ambulatory blood pressure monitoring; HT – arterial hypertension;
PH – primary hypertension; TOD – target organ damage 
Fig. 1 Scheme of the
study design
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cIMT (mm) 0.44±0.05 0.42±0.04 0.0001
cIMT-SDS 1.4±1.5 0.9±1.3 0.008
WCSA (mm
2) 7.5±1.3 6.9±1.2 0.002
WCSA-SDS 1.05±1.5 0.2±1.3 0.001
fIMT (mm) 0.34±0.04 0.33±0.03 n.s.
fIMT-SDS 0.01±1.4 −0.2±1.1 n.s.
Left ventricular mass (g) 161±55 148±44 0.0001
Left ventricular mass index (g/height
2.7) 38.5±10.7 35.2±7.5 0.0001
Left ventricular hypertrophy (%) 40 (46.5%) 27 (31.4%) 0.0001
Severe left ventricular hypertrophy (%) 10 (11.6%) 1 (1.2%) 0.006
Left ventricular hypertrophy diagnosed
with age- and gender-specific cut-off values (%)
39 (45.3%) 24 (27.9%) 0.0001
Metabolic syndrome (%) 13 (15.1%) 6 (7%) 0.0001
Cholesterol (mg/dl) 175±36 168±28 0.02
Triglycerides (mg/dl) 87±41 88±38 n.s.
HDL-cholesterol (mg/dl) 44±8 44±8 n.s.
LDL-cholesterol (mg/dl) 115±33 107±26 0.001
ApoA1 (mg/dl) 1.29±0.29 1.26±0.30 n.s.
ApoB (mg/dl) 0.90±0.25 0.86±0.24 n.s.
ApoA1/apoB 1.5±0.4 1.6±0.6 n.s.
Lipoprotein (a) (mg/dl) 18.0±14.1 14.1±7.7 n.s.
Uric acid (mg/dl) 5.5±1.3 5.3±1.2 0.056
Serum creatinine (mg/dl) 0.8±0.2
eGFR (ml/min/1.73 m
2) 131±18
hsCRP (mg/l) 1.1±1.0 0.7±0.7 0.002
Fasting glucose (mg/dl) 84±5 84±7 n.s.
Fasting insulin (IU/ml) 14.7±6.9 18.2±23.1 n.s.
HOMA-IR 3.1±1.5 3.2±1.6 n.s.
ISI 4.5±1.7 4.7±1.7 n.s.
Homocysteine (μmol/l) 9.7±2.5 10.0±2.6 n.s.
Leptin (ng/ml) 16.2±15.2 9.8±9.5 0.04
Adiponectin (μg/ml) 10.7±4.7 9.8±6.4 n.s.
Table 2 Markers of target
organ damage and laboratory
data obtained at the start and
after 12 months of treatment
cIMT carotid intima-media
thickness; WCSA carotid wall
cross-sectional area; fIMT
femoral intima-media thickness;
HDL-cholesterol high density
lipoprotein cholesterol; LDL-
cholesterol low density
lipoprotein cholesterol; ApoA1
apoprotein A1; ApoB
apoprotein B; eGFR estimated
glomerular filtration rate; hsCRP
high-sensitivity C reactive
protein; HOMA-IR homeostasis
model assessment for insulin
resistance; ISI insulin sensitivity
index
Table 3 Differences between patients with regression of target organ damage (TOD) and in whom TOD was stable or progressed
Variable Decreased Stable or increased p
LVMi (n=58) LVMi (n=28)
ΔWaist-to-hip ratio −0.01±0.14 0.07±0.02 0.02
ΔWaist −3.2±6.4 2.5±5.1 0.001
ΔHOMA-IR −0.3±1.7 0.3±1.2 0.05
cIMT-SDS (n=56) cIMT-SDS (n=30)
ΔCRP −0.5±1.1 −0.07±0.3 0.05
WCSA-SDS (n=56) WCSA (n=30)
ΔWaist-to-hip ratio −0.05±0.06 0.02±0.03 0.05
ΔWaist circumference −4.8±7.5 3.0±5.3 0.005
ΔISI 0.6±1.4 −0.5±1.2 0.02
Only the significant differences are shown
LVMi left ventricular mass index; HOMA-IR homeostasis model assessment for insulin resistance; ISI insulin sensitivity index; hsCRP high
sensitivity C reactive protein; WCSA carotid wall cross-sectional area; cIMT carotid intima-media thickness
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office BP and ABPM in predicting risk of left ventricular
hypertrophy at the initial visit [22]. We performed ABPM
in all children both at the start and after 12 months of
treatment. Moreover, the decisions to intensify treatment
were based on ABPM results after 3 and 6 months. Thus,
we classified the severity of hypertension according to
recently proposed criteria based on SBP values and SBP
loads [9].
The clinical characteristics of our patients in terms of
intermediate phenotype, metabolic abnormalities, and the
extent of TOD were typical for children with PH [23, 24].
Subclinical cardiovascular injury and left ventricular hyper-
trophy are observed in 30–40% of children with PH already
at diagnosis of elevated blood pressure [1–3, 23–25]. We
used two cut-offs for left ventricular hypertrophy, i.e. for
LVMi above the 95th percentile. One was based on the
standardization of LVM to height and recommended by the
4th Task Report and by the European Society of Hyperten-
sion [7, 26], and the second was based on the standardization
of LVM to height, age, and gender, and was proposed
recently by Khoury et al. [15]. However, we did not find
significant differences in the prevalence of left ventricular
hypertrophy when using the two methods. It is because the
age range of our patients was rather narrow and significant
differences between the two methods of indexation of LVM
are evident at younger and older ages.
We found that standard antihypertensive treatment based
on lifestyle changes and/or blockade of the renin-angiotensin
system is effective. Because BP, and particularly pulse
pressure, is the main determinant of IMT, one can assume
that an increased IMTis an indirect marker of long-lasting BP
elevation and by causing increased stiffness may lead to
resistance to treatment [27]. It corresponds with greater basal
inflammatory activity shown as greater basal concentrations
of hsCRP in non-responders as well as significant decreases
in insulin resistance among responders. Moreover, a decrease
in inflammatory activity expressed as a decrease in hsCRP
concentration predicted a decrease in carotid IMT. In another
study it was shown that innate immunity is activated in
children with PH and that there is a significant relationship
between markers of immune activity and TOD, between
metabolic abnormalities and the amount of visceral fat [28].
These findings suggest that markers of inflammatory
activity, insulin resistance, hypertensive arteriopathy, i.e.
IMT, and of visceral obesity should be included as criteria
for early and more intensive treatment in hypertensive
children.
In adults, the extent of TOD correlates with BP and the
lowering of BP leads to regression of TOD. It was also
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Fig. 3 Linear regression of correlation between the change in the
WHtR and the change in wall cross-sectional area (WCSA): r=0.528,
p=0.002
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Fig. 2 Linear correlation between decrease in waist-to-height ratio
(WHtR)anddecreaseinleftventricular mass(LVMi): r=0.263, p=0.03)
Table 4 Coefficients of Spearman’s rank correlation test between
pairs of variables describing regression of target organ damage and
independent variables
rp
ΔLVMi vs ΔWHtR 0.263 0.03
ΔLVMi vs Δwaist circumference 0.318 0.01
ΔcIMT-SDS vs ΔhsCRP 0.332 0.01
ΔWCSA-SDS vs Δwaist circumference 0.490 0.006
ΔWCSA-SDS vs ΔWHtR 0.486 0.007
ΔWCSA-SDS vs ΔWHR 0.521 0.003
ΔWCSA vs ΔWHtR 0.528 0.002
ΔWCSA vs ΔWHR 0.528 0.002
ΔWCSA vs Δwaist circumference 0.573 0.001
LVMi left ventricular mass index; WHTR waist to height ratio; hsCRP
high sensitivity C reactive protein; WCSA carotid wall cross sectional
area; WHR waist to hip ratio
2496 Pediatr Nephrol (2010) 25:2489–2499documented in cross-sectional studies that in children with
PH, the LVH correlates with hypertension severity [19–21].
In contrast, we did not find any direct relation between the
hypotensive effect and regression of TOD. However,
pediatric criteria for the diagnosis of hypertension are based
on percentiles rather than absolute values. The measured
absolute values of BP were numerically much lower than in
adults with PH and on average did not even fulfill criteria
for the diagnosis of hypertension in adults. Second, BP
lowered by an average of 4 mmHg and this may be too
small a decrement to document the relation between the
hypotensive effect and regression of TOD. On the other
hand, BP measured both in the office and as ABPM
physiologically rises with increasing age and height by
approximately 1–2.5 mmHg per year in adolescents.
Therefore, the observed absolute average decrease of
4 mmHg over 1 year of therapy is in fact even greater,
because after 12 months our patients were both older and
taller on average by 3 cm, and their 95th percentile values
for BP (i.e. the upper limit of normal values) also increased,
especially in adolescent boys.
Target organ damage in adolescents with PH is strictly
related to metabolic abnormalities, central fat accumulation,
and MS [18]. In the present study, the extent of metabolic
abnormalities, including the prevalence of MS, was similar
to that of our previous study [18]. We found that the
prevalence of MS decreased in parallel to the regression of
TOD. In addition, TOD regression was determined by a
redistribution of adipose tissue, a decrease in central fat
mass, and an increase in insulin sensitivity. This confirms
the previous findings and also the hypothesis that metabolic
abnormalities are the main determinants of TOD in
adolescents with PH. It also indicates that the treatment of
adolescents with PH should be complex, including the
monitoring of anthropometrical parameters. A lack of
significant changes in the BMI with a significant decrease
in the WHR and WC indicate an increase in lean body
mass, probably due to increased physical activity secondary
to the adoption of lifestyle changes. In contrast, BMI,
WHR, and WC did not change in patients who showed no
regression of the TOD.
The potential effect of the pharmacological treatment on
the redistribution of the fat tissue is another important issue.
A prospective study showed that treatment with ACEi
increases insulin sensitivity in adults [29]. There are also
data indicating that ARBs increase insulin sensitivity by
activation of PPARγ [30]. Because fat is a metabolically
active tissue and its distribution is under hormonal control,
it may well be that various pharmacological agents have a
variable influence on the amount and distribution of fat
tissue. It was recently shown that treatment with candesar-
tan had no effect on insulin sensitivity and fat tissue
distribution, but treatment with thiazides resulted in
increased insulin resistance and an increase in visceral fat
[31]. Our patients were instructed to increase their physical
activity and all received dietary advice during each clinic
visit. Thus, we were not able to separate the effects of
pharmacological therapy from non-pharmacological therapy.
The main limitation of our study is its observational
design. Therefore, the effects of non-pharmacological and
pharmacological therapy could not be separated. Similarly,
the effects of different antihypertensive drugs are difficult
to compare. Second, because the adoption of lifestyle
modifications includes both diet and physical activity, it is
impossible to analyze the effects of each intervention
separately. The other potential bias is compliance with
treatment. Although we monitored patients every 3 months
we were not able to fully eliminate drug non-compliance in
those patients who did not lower BP.
Another important issue is the potential effect of the
regression to the mean phenomenon. However, in all
patients elevated BP was detected on many occasions
before referral to our center and finally, diagnosis of PH
was confirmed by ABPM. Moreover, we used ABPM both
to classify the severity of hypertension and to monitor the
effectiveness of the treatment. There is also the possibility
that regression to the mean phenomenon may play a role in
the observed decrease in LVMi and IMT. In contrast to BP
measurements, results of both ECHO and ultrasound
measurements are mainly dependent on investigator skills.
Because changes in LVMi and IMT correlated with other
investigator-independent variables, such as anthropometrical
parameters, inflammatory activity, and insulin sensitivity
markers, it seems less probable that the regression to the
mean phenomenon played a significant role in the detection
of changes in LVMi and IMT.
Because most adolescents with PH present with absolute
BP values that could be classified as falling within the pre-
hypertensive range for adults, it is intriguing that a good
response to treatment in terms of BP lowering, regression
of TOD, and a reduction in metabolic abnormalities might
enable discontinuation of pharmacological treatment and
continuation of only lifestyle modifications. Such an
approach was tested in the TROPHY study with pre-
hypertensive, middle-aged adults [32]. It seems logical that
earlier treatment in a high-risk group of adolescents at an
early stage of cardiovascular disease would have a more
pronounced and long-lasting effect than in adults who are
already hypertensive and one to two decades older.
Conclusions
Our results indicate that standard therapy of children with
PH leads to significant BP lowering, regression of TOD and
normalization of metabolic abnormalities. Decrease in
Pediatr Nephrol (2010) 25:2489–2499 2497blood pressure was associated with lower IMT, inflammato-
ry activity, and increased insulin sensitivity. However, the
main determinant of TOD regression was not blood pressure
lowering by itself, but redistribution of the fat mass with a
decreaseinabdominalobesity.Thepositiveeffectofchanges
in body composition with an increase in lean body mass
indicates that intensive non-pharmacological treatment
might be helpful in reversing TOD.
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